John Shelmet, MD
Endocrinology, Diabetes & Metabolism · Lawrenceville, NJNPI 1770699480
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $628 and has fallen 90.3% since, to $61 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NJ, where the typical reported total is $1,953.
Across 88 payments — averaging $13.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$252
- Novo Nordisk$220
- Lilly USA, LLC$170
- Boehringer Ingelheim$163
- Abbott$108
- AstraZeneca$102
- plus $208 from 7 others
Across 38 payments — averaging $2243.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$85K
What the payments were for
- Food & beverage$1,20799%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 18 | $252 |
| Novo Nordisk | 16 | $220 |
| Lilly USA, LLC | 12 | $170 |
| Boehringer Ingelheim | 12 | $163 |
| Abbott | 7 | $108 |
| AstraZeneca | 8 | $102 |
| Insulet Corporation | 4 | $60 |
| Merck | 4 | $53 |
| Dexcom, Inc. | 2 | $28 |
| IBSA Pharma Inc. | 2 | $27 |
| Amgen | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $13 |
How this compares
$1,223 in reported general payments places this provider in the 40th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $147,806 |
| JanuviaSitagliptin Phosphate | 133 | $139,636 |
| TrulicityDulaglutide | 45 | $75,539 |
| RybelsusSemaglutide | 41 | $55,410 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $48,157 |
| MounjaroTirzepatide | 31 | $44,170 |
| TradjentaLinagliptin | 35 | $37,019 |
| JardianceEmpagliflozin | 30 | $33,913 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 23 | $30,841 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $27,299 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $22,134 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $22,102 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $21,555 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $18,615 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $17,621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $220 | $203,215127 claims |
| MerckJanuvia, Janumet Xr | $53 | $157,257145 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $170 | $127,09995 claims |
| Boehringer IngelheimTradjenta, Jardiance | $163 | $70,93265 claims |
| Sanofi-aventis U.S. LLCLantus | $252 | $3,39913 claims |
| IBSA Pharma Inc.Tirosint | $27 | $2,28115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Lawrenceville
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.